Contributing Authors: GO2 for Lung Cancer Associate Director, Clinical Research, Andrew Ciupek, PhD and Manager, Precision Medicine & Navigation, Matthew Reiss, MSE, PhD Each year, researchers, physicians, and industry partners gather at the European Society for Medical Oncology [...]
On Nov. 16, 2023, the U.S. Food and Drug Administration (FDA) approved Augtyro (repotrectinib) for people living with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a ROS1 gene mutation. The approval was based on results from [...]
Question: I’ve just been diagnosed with lung cancer, and my doctor said I may need to have surgery. What can I expect? Answer: Your healthcare team will explain the best type of surgery for you, but the goal will [...]
Author: GO2 for Lung Cancer Specialist, Science & Research, Brittney Nichols MPH, BSN-RN Each year, scientists and doctors from across the globe gather at IASLC’s World Conference on Lung Cancer (WCLC) to discuss the latest and greatest in lung [...]
Author: GO2 for Lung Cancer Associate Director, Clinical Research, Andrew Ciupek, PhD With an increasing number of targeted therapies becoming available, making treatment decisions based on the results of biomarker testing has become an essential part of cancer care [...]
Author: GO2 for Lung Cancer's Specialist, Science & Research, Brittney Nichols MPH, BSN-RN The IASLC annual World Conference on Lung Cancer (WCLC) unites lung cancer professionals from across the world to connect and share insights. This goes beyond the [...]
Author: GO2 for Lung Cancer Treatment and Trials Navigator, Renee Botello MSc Tagrisso (osimertinib) has been the treatment of choice and effective standard of care option for the treatment of EGFR+ non-small cell lung cancer (NSCLC) since its FDA [...]
On October 16, 2023, the U.S. Food and Drug Administration (FDA) approved a new treatment plan for people receiving Keytruda (pembrolizumab) for resectable non-small cell lung cancer (NSCLC). This approval is based on results from the KEYNOTE-671 (NCT03425643) clinical [...]
On October 11, 2023, the U.S. Food and Drug Administration (FDA) approved a combination of Braftovi (encorafenib) and Mektovi (binimetinib) for people with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation. BRAF is a less common [...]
Question: I have many questions about my lung cancer diagnosis and treatment options, but I’m worried about bothering my doctor. What should I do? Answer:* If you have an oncologist who makes you feel like you shouldn’t be contacting them, [...]